135 related articles for article (PubMed ID: 27039922)
1. Brain-metastatic Breast Cancer: Clinical Considerations and Pharmacological Approaches.
Andrade AC; Ferruzzi DS; Panis C
Anticancer Agents Med Chem; 2016; 16(12):1523-1528. PubMed ID: 27039922
[TBL] [Abstract][Full Text] [Related]
2. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.
Chien AJ; Rugo HS
Breast Cancer Res Treat; 2013 Jan; 137(1):1-12. PubMed ID: 23143215
[TBL] [Abstract][Full Text] [Related]
3. Targeting HER2 in Advanced Breast Cancer.
Zhu X; Joy AA
Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
[TBL] [Abstract][Full Text] [Related]
4. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
[TBL] [Abstract][Full Text] [Related]
5. Cabazitaxel Plus Lapatinib as Therapy for HER2
Yardley DA; Hart LL; Ward PJ; Wright GL; Shastry M; Finney L; DeBusk LM; Hainsworth JD
Clin Breast Cancer; 2018 Oct; 18(5):e781-e787. PubMed ID: 29678476
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management.
Lin NU; Gaspar LE; Soffietti R
Am Soc Clin Oncol Educ Book; 2017; 37():45-56. PubMed ID: 28561683
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
8. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer metastasis to the central nervous system.
Weil RJ; Palmieri DC; Bronder JL; Stark AM; Steeg PS
Am J Pathol; 2005 Oct; 167(4):913-20. PubMed ID: 16192626
[TBL] [Abstract][Full Text] [Related]
10. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Serpico D; Porcu L; Tessari A; Gevorgyan A; Bregni G; Galli G; de Braud F; Torri V; Di Cosimo S
Clin Transl Oncol; 2015 Jul; 17(7):530-8. PubMed ID: 25604128
[TBL] [Abstract][Full Text] [Related]
11. Current therapeutic options for breast cancer central nervous system metastases.
Hemphill MB; Lawrence JA
Curr Treat Options Oncol; 2008 Feb; 9(1):41-50. PubMed ID: 18392684
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular mechanisms underlying brain metastasis of breast cancer.
Hosonaga M; Saya H; Arima Y
Cancer Metastasis Rev; 2020 Sep; 39(3):711-720. PubMed ID: 32399646
[TBL] [Abstract][Full Text] [Related]
14. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
Melisko ME; Glantz M; Rugo HS
Nat Clin Pract Oncol; 2009 Jan; 6(1):25-33. PubMed ID: 18936791
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge.
Stemmler HJ; Heinemann V
Oncologist; 2008 Jul; 13(7):739-50. PubMed ID: 18614587
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
[TBL] [Abstract][Full Text] [Related]
17. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman RA; Gelman RS; Wefel JS; Melisko ME; Hess KR; Connolly RM; Van Poznak CH; Niravath PA; Puhalla SL; Ibrahim N; Blackwell KL; Moy B; Herold C; Liu MC; Lowe A; Agar NY; Ryabin N; Farooq S; Lawler E; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU
J Clin Oncol; 2016 Mar; 34(9):945-52. PubMed ID: 26834058
[TBL] [Abstract][Full Text] [Related]
18. [Brain metastasis of breast tumors and blood brain barrier].
Diéras V; Pierga JY
Bull Cancer; 2011 Apr; 98(4):385-9. PubMed ID: 21527366
[TBL] [Abstract][Full Text] [Related]
19. Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions.
Soleja M; Rimawi MF
Curr Probl Cancer; 2016; 40(2-4):117-129. PubMed ID: 27839746
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
